布地奈德福莫特罗对哮喘患者血清中CCL28的影响研究
Effect of budesonide fomoterol on CCL28 in asthma patients
史莹 1周丹阳 1谷伟1
作者信息
- 1. 南京市第一医院 呼吸科,江苏 南京 210006
- 折叠
摘要
目的 研究布地奈德福莫特罗对哮喘患者血清中CCL28的影响.方法 取轻中度急性发作期哮喘患者的静脉血,分离血清后,检测血清中CCL28的含量,对患者进行布地奈德福莫特罗干预,1 w后复查血清中的CCL28.结果 急性发作期哮喘患者血清中CCL28为(37.58±3.64)ng/mL,布地奈德福莫特罗干预后患者血清CCL28降为(10.37±1.05)ng/mL.结论 布地奈德福莫特罗能明显降低CCL28,可能对抑制哮喘急性期嗜酸性细胞炎症起重要作用.
Abstract
Objective To investigate the effect of budesonide fomoterol on CCL28 expression in the serum of asthma patients. Methods Asthma patients in acute exacerbation were taken the venous blood. After the separation of serum, the content of CCL28 were tested. The patients received budesonide fomoterol treatment. All the patients received CCL28 detection one week later. Results The CCL28 level in patients of acute exacerbation was (37.58±3.64) ng/mL. After budesonide fomoterol treatment, the CCL28 level in patients was (10.37±1.05) ng/mL. Conclusion Budesonide fomoterol could significantly reduce CCL28 level of asthma patients in acute exacerbation, and may play an important role in inhibiting the eosinophilic inflammation in acute asthma.
关键词
哮喘/CCL28/布地奈德福莫特罗Key words
asthma/CCL28/budesonide fomoterol引用本文复制引用
出版年
2017
NETL
NSTL
维普
万方数据